These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 3511171)

  • 1. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.
    Uckun FM; Gajl-Peczalska KJ; Kersey JH; Houston LL; Vallera DA
    J Exp Med; 1986 Feb; 163(2):347-68. PubMed ID: 3511171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
    Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
    Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
    Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
    J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
    Ramakrishnan S; Uckun FM; Houston LL
    J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
    Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells.
    Waddick KG; Myers DE; Gunther R; Chelstrom LM; Chandan-Langlie M; Irvin JD; Tumer N; Uckun FM
    Blood; 1995 Dec; 86(11):4228-33. PubMed ID: 7492781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
    Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
    J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
    Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
    Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
    J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
    Uckun FM; Ramakrishnan S; Houston LL
    J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
    Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
    Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
    Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Wendorf HR; Schneider EA; Covalciuc K; Johnson B; Clementson D; Irvin JD; Myers DE; Uckun FM
    Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
    Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
    Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
    Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.